SCHEMBL25263288

SCHEMBL25263288

Cn1c(N2CCCC(Nc3ncc(C(F)(F)F)cn3)C2)nc2cc(N)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNK O75909 1/20 0.38
CDK12 Q9NYV4 1/20 0.38
KMT2A Q03164 3/20 0.36
MAPK3 P27361 1/20 0.36
IDH2 P48735 1/20 0.36
IL1B P01584 4/20 0.35
NLRP3 Q96P20 3/20 0.35
MEN1 O00255 1/20 0.35
MCHR1 Q99705 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
CTSC P53634 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ULK1 O75385 2/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
ULK2 Q8IYT8 1/20 0.35
HRH4 Q9H3N8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25216715 1.00 CCNK (0.38) CCNKCDK12KMT2AMAPK3IDH2
SCHEMBL30533989 1.00 CCNK (0.38) CCNKCDK12KMT2AMAPK3IDH2
SCHEMBL25268397 0.89 KMT2A (0.36) CCNKCDK12KMT2AIDH2IL1B
SCHEMBL30533952 0.89 KMT2A (0.36) CCNKCDK12KMT2AIDH2IL1B
SCHEMBL25217556 0.89 KMT2A (0.36) CCNKCDK12KMT2AIDH2IL1B
SCHEMBL30533949 0.85 ALDH1A1 (0.41) CCNKCDK12KMT2AMEN1LMNA
SCHEMBL25219563 0.85 ALDH1A1 (0.41) CCNKCDK12KMT2AMEN1LMNA
SCHEMBL25260927 0.85 ALDH1A1 (0.41) CCNKCDK12KMT2AMEN1LMNA
SCHEMBL25225779 0.84 CDK7 (0.39) MAPK3TRPV1ULK1ULK2HRH4
SCHEMBL25269859 0.84 CDK7 (0.39) MAPK3TRPV1ULK1ULK2HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS INCYTE CORPORATION 2023-06-29 US disclosed
WO-2023102184-A1 BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS CDK12, CDK1, CDK2 CCNK 17/4885CDK12 1/4885KMT2A 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.